Memorial Sloan Kettering Cancer Center
Avatar

FDA Approval Clinical Implications: Inavolisib With Palbociclib and Fulvestrant for PIK3CA-Mutated, Endocrine-Resistant HR+/HER2- aBC

By Memorial Sloan Kettering Cancer Center FEATURING Komal Jhaveri
By Memorial Sloan Kettering Cancer Center FEATURING Komal Jhaveri
540 views
October 17, 2024
Comments 0
Login to view comments. Click here to Login

Featured Video

03:15
Lilly Medical Affairs

Unmet Needs and Resistance Mechanisms in Patients With HR+, HER2- MB…

Feat. W. Mchayleh

Featured Video

05:59
Lilly Medical Affairs

Progression on First-Line Therapy in HR+, HER2- MBC: Treatments and …

Feat. J. O’Shaughnessy

Recommended

25:08

ASCO® 2024 Breast Cancer Highlights - Monday Morning Practice

2024 ASCO® Annual Meeting Insights Hub

S. Tolaney, H. Rugo

4.1K views

·

5 months ago
12:14

ASCO® 2024 Breast Cancer Highlights: Top 5 Abstracts - DESTINY-Breas…

2024 ASCO® Annual Meeting Insights Hub

P. Tarantino

2.1K views

·

4 months ago
10:53

Integrating Oral Therapy for Patients With HR+/HER2- Early Stage BC

Kirollos Hanna

2.1K views

·

4 months ago
11:31

ASCO® 2023 Top 5 Abstracts Summary: "SONIA, NATALEE, PHERGain, TROPI…

Insights from 2023 ASCO® Annual Meeting

P. Tarantino

8.2K views

·

1 year ago
07:23

Advanced Stage HR+ BC: Fine-Tuning Sequential Endocrine and Targeted…

Total Health

R. O'Regan

1.3K views

·

8 months ago
12:35

SABCS 2023 Summary: "What Is the Appropriate 1L Therapy for ER+ mBC?"

Insights from 2023 SABCS

S. Tolaney, H. Rugo

3.0K views

·

10 months ago
09:55

ASCO® 2024 Insights: "The ABCs of ADCs - What Does the Future Hold?"

2024 ASCO® Annual Meeting Insights Hub

E. Hamilton

1.4K views

·

5 months ago
03:40

SABCS 2023 Insights: "CAPItello-291 Trial - Capivasertib & Fulvestra…

Integrity CE

A. Bardia

1.5K views

·

9 months ago
17:12

Strategies for Managing Toxicities of Oral Oncolytics in Breast Canc…

UNC Lineberger Comprehensive Cancer Center

A. Faso, B. Patel, K. Chen

1.5K views

·

2 months ago
14:16

Year in Review: Breast Cancer

Dana-Farber Cancer Institute

P. Tarantino

2.4K views

·

9 months ago
17:39

2023 Menopause Update

Yale School of Medicine

M. Minkin

9.0K views

·

1 year ago
14:52

ESMO 2024 Summary: Top 5 Breast Cancer Abstracts - NATALEE, DESTINY-…

2024 ESMO Annual Meeting Insights Hub

P. Tarantino

720 views

·

1 month ago
05:43

Neoadjuvant Chemo for HR+ BC: Year in Review

Total Health

C. Ma

975 views

·

8 months ago
36:18

Metastatic Breast Cancer Comprehensive Review: ESMO Breast 2024 Awar…

Insights from ESMO Breast 2024 Annual Meeting

H. Rugo

1.2K views

·

5 months ago
17:20

ESMO 2023 Summary: "Top 5 Breast Cancer Studies Including KEYNOTE-75…

Insights from 2023 ESMO Annual Meeting

P. Tarantino

2.1K views

·

1 year ago
57:44

Vogl,NY on How to Ask Good Questions at Medical Meetings

Vogl, NY

S. Vogl

5.1K views

·

1 year ago
27:01

CDK4/6 Inhibitor Therapy in Early-Stage HR+/HER2- BC

Scripps Health

S. Sammons

1.7K views

·

8 months ago
33:44

ASCO® 2024 Expert Recap: "Metastatic Breast Cancer Deep Dive & Clini…

2024 ASCO® Annual Meeting Insights Hub

S. Tolaney, H. Rugo

919 views

·

4 months ago
16:19

Optimizing Adjuvant Treatment in High-Risk HR+/HER2- eBC: Patient Se…

Wassim Mchayleh

874 views

·

3 months ago
22:34

What's New in Breast Cancer?

Dana-Farber Cancer Institute

S. Tolaney

1.5K views

·

10 months ago
AUTOPLAY